Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

PLYMOUTH MEETING, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that development partner MedImmune, Inc. has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528. Genaera and MedImmune entered into a collaborative licensing agreement for this program in 2001.

"This study begins another important step in evaluating the potential of the anti-IL-9 antibody as a new, long-term maintenance or controller therapy for symptomatic, persistent asthma," said Jack Armstrong, President and Chief Executive Officer of Genaera. "We are pleased that the anti-IL-9 antibody is progressing through MedImmune's respiratory inflammation pipeline and remain excited to be part of this partnership. Furthermore, we are optimistic that this study will add to the body of clinical and preclinical data supporting development of MEDI-528 as a potential therapy for this very serious and unfortunately all too common disease."

Two previous Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. MedImmune is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. Plans to initiate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 Edwards ... the science of heart valves and hemodynamic monitoring, today announced ... company,s Board of Directors. "Bob is an ardent ... been a true privilege to have him on Edwards, board ... A. Mussallem , Edwards, chairman and CEO.  "Bob has provided ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
(Date:8/2/2015)... ... 2015 , ... Molecular biologists in New South Wales say a protein linked ... just posted an article on the new research. Click here to read it ... expression in tissue samples from 42 patients with peritoneal mesothelioma and found a direct ...
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” ... when you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, ... is one of the central concepts of this tradition. According to the wisdom of this ...
(Date:8/1/2015)... ... , ... Calvary Hospital today announced that it is embarking on a yearlong ... to bring this Torah – dating from 1880 – back to kosher status, so ... , Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of ... unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what ... of both companies have agreed to join their missions of purpose together to change ...
Breaking Medicine News(10 mins):Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3
... procedures and techniques discussed at surgeons, conference, ... surgery patients are getting back on their feet ... introduction of tissue graft products, bone anchors, radio,frequency ... invasive treatments and speedier recovery times. More than ...
... TIKVA, Israel, February 20 012,Smile.Communications (Nasdaq: ... fourth quarter results on Tuesday , February 26, ... day, Management will host an interactive,teleconference to discuss ... call one of the following access numbers several ...
... Worst Among Racial Minorities, the Uninsured and,Medicare ... New data revealing,decreasing trends in cancer deaths ... cancer deaths in particular, highlight the remarkable ... lifesaving potential of these,tests is unrealized for ...
... Publications today announced,that several stem cell experts, including ... medicine services (oncology) at Case Western Reserve,University, Wise ... W.M. Keck,Center for Collaborative Neuroscience and a professor ... R. Lyon, M.D., the chief of orthopaedic,surgery at ...
... Accenx Technologies, Inc., a,leading company in electronic medical ... and BayCare Health System of,Clearwater, FL, announced today ... implement its RyTRAK HIE system to exchange clinical ... health care providers to exchange clinical data,seamlessly between ...
... Institute of Standards and Technology (NIST) can detect nuclear ... through a novel microchip. The prototype chip device, developed ... California, may have wide application as a sensitive chemical ... drugs. , As described in Proceedings of the National ...
Cached Medicine News:Health News:Achilles Tendon Surgery Advances Speed Recovery 2Health News:012 Smile.Communication's Fourth Quarter Earnings Release and Conference Call Scheduled for February 26, 2008 2Health News:012 Smile.Communication's Fourth Quarter Earnings Release and Conference Call Scheduled for February 26, 2008 3Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 2Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 3Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 4Health News:Stem Cell Experts and New York Lt. Gov. David Paterson to Participate in 3rd Annual Stem Cell Summit as Keynote Speakers 2Health News:Stem Cell Experts and New York Lt. Gov. David Paterson to Participate in 3rd Annual Stem Cell Summit as Keynote Speakers 3Health News:BayCare Health System Collaborates With Accenx to Provide Reliable Exchange of Information 2Health News:'NMR on a chip' features NIST magnetic mini-sensor 2
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Medicine Products: